+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia Pacific Biodefense Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product, and Geography

  • ID: 5028564
  • Report
  • April 2020
  • Region: Asia Pacific
  • 100 pages
  • The Insight Partners
UP TO OFF
until Jun 30th 2020
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Altimmune
  • Bavarian Nordic
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Pluristem Therapeutics
  • MORE
Asia Pacific, the Biodefense Market, is anticipated to reach US$ 1,520.67 Mn in 2027 from US$ 723.70 Mn in 2019. The market is projected to grow with a CAGR of 9.8% from 2020-2027.

The Biodefense Market is growing primarily due to the presence of favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM. Restraining factors, such as low R&D funding by government in developing and underdeveloped economies likely to damage the growth of the market in the coming years. Additionally, increased adoption of technologies and predictive analytics to reshape biodefense market are likely to increase the growth of the biopharmaceuticals contract manufacturing in the forecast period.

Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.

Every year, the government is spending heavily on the R&D of vaccines to stay prepared for any bioterrorism attacks. For instance, in Japan reinforcing public health biopreparedness and preventive measures (pathogen control) were followed by enhancement of R&D and networking for biosecurity as a key agenda under “Safe and Secure Society” initiative. Pandemic preparedness was significantly improved after 2009 with the Special Measures Act for crisis management. More recently, the National Institute of Allergy and Infectious Diseases (NIAID) Office of Biodefense Research and Surety has been engaged with Japan in medical research issues involved with biosecurity and biodefense under the U.S. - Japan Framework Initiative for a Safe and Secure Society. As the government engages in these current and future policy activities, understanding the existing biosecurity and biodefense policy, the pharmaceutical companies operating in the biodefense market have considerable opportunities to expand and be prepared for any bioterrorism. The initiatives of governments open a window of opportunities for the firms involved in the biodefense sector.

Moreover, due to factors such as increasing border threats, rising national security concerns, and changing dynamics of warfare, countries such as China, Japan, India in Asia Pacific are inclined towards enhancing their missile weapon store. They are also modernizing their old missiles with the new propulsion system and warheads. Hence, as the threat for biological weapon and nuclear armed ICBM is increasing, governments of various countries are actively funding for biodefense, thereby, positively propelling the Asia Pacific market. Thus, owing to the factors mentioned above are likely to boost the growth of the Biodefense Market in Asia Pacific during the forecast period.

In 2019, the anthrax segment accounted for the largest market share in the Biodefense Market in Asia Pacific. The segment is expected to continue its dominance over the forecast period owing to increasing funding by the governments of other countries to develop and stockpile adequate vaccines against anthrax mainly through a variety of initiatives in Asian countries, such as safe and security initiative , Special Measures Act for Pandemic preparedness, Civilian Protection Act and the Defense Research and Development Establishment (DRDE).

Some of the significant secondary sources for cold plasma equipment included in the report are the World Health Organization (WHO) and the Food and Drug Administration (FDA).

Reasons to Buy
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific biodefense market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific biodefense market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Altimmune
  • Bavarian Nordic
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Pluristem Therapeutics
  • MORE
1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Biodefense market - By Product
1.3.2 Asia Pacific Biodefense market - By Country

2. Asia Pacific Biodefense market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Biodefense market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 4.2.1 Biodefense market - Asia Pacific PEST Analysis
4.3 Expert Opinion

5. Asia Pacific Biodefense market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Presence of Favourable Government Initiatives
5.1.2 Increase in the Number of Naturally Occurring Outbreaks
5.1.3 Increasing Threat of Biological Weapons and Nuclear Armed ICBM
5.2 Key Market Restraints
5.2.1 Low R&D Funding by Government in Developing and Underdeveloped Economies
5.3 Key Market Opportunities
5.3.1 Increased Adoption of Technologies
5.4 Future Trends
5.4.1 Predictive Analytics to Reshape Biodefense Market
5.5 Impact Analysis

6. Biodefense market - Asia Pacific Analysis
6.1 Asia Pacific Biodefense market Revenue Forecasts and Analysis

7. Asia Pacific Biodefense market Analysis And Forecasts To 2027 - By Product
7.1 Overview
7.2 Asia Pacific Biodefense market, By Product 2019 & 2027 (%)
7.2.1 Asia Pacific Biodefense market Revenue and Forecasts to 2027, By Product (US$ Mn)
7.3 Anthrax
7.3.1 Overview
7.3.2 Asia Pacific Anthrax Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Small pox
7.4.1 Overview
7.4.2 Asia Pacific Small Pox Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Botulism
7.5.1 Overview
7.5.2 Asia Pacific Botulism Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Radiation/Nuclear
7.6.1 Overview
7.6.2 Asia Pacific Radiation/Nuclear Market Revenue and Forecasts to 2027 (US$ Mn)
7.7 Others
7.7.1 Overview
7.7.2 Asia Pacific Others Market Revenue and Forecasts to 2027 (US$ Mn)

8. Biodefense market Revenue and Forecasts To 2027 - Geographical Analysis
8.1 Asia Pacific Biodefense market Revenue and Forecasts To 2027
8.1.1 Overview
8.1.2 Asia Pacific: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.3 Asia Pacific: Biodefense Market, by Product, 2018-2027 (USD Million)
8.1.4 Asia Pacific: Biodefense Market, by Country, 2018 & 2027 (%)
8.1.5 China: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.5.1 China: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.5.2 China: Biodefense Market, by Product Type, 2018-2027 (USD Million)
8.1.6 Japan: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.6.1 Japan: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.6.2 Japan: Biodefense Market, by Product Type, 2018-2027 (USD Million)
8.1.7 India: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.7.1 India: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.7.2 India: Biodefense Market, by Product Type, 2018-2027 (USD Million)
8.1.8 South Korea: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.8.1 South Korea: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.8.2 South Korea: Biodefense Market, by Product Type, 2018-2027 (USD Million)
8.1.9 Australia: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.9.1 Australia: Biodefense Market - Revenue and Forecast to 2027 (USD Million)
8.1.9.2 Australia: Biodefense Market, by Product Type, 2018-2027 (USD Million)

9. Impact of Covid-19 Pandemic On Asia Pacific Biodefense Market
9.1 Asia-Pacific: Impact assessment of COVID-19 Pandemic

10. Asia Pacific Biodefense market Industry Landscape
10.1 Overview
10.2 Growth Strategies in The Biodefense Market, 2016-2020
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview

11. COMPANY PROFILES
11.1 Bavarian Nordic
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Alnylam Pharmaceuticals, Inc.
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 SIGA Technologies
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Emergent BioSolutions Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Cleveland Bio Labs
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments

12. Appendix
12.1 About the Publisher
12.2 Glossary of Terms
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Bavarian Nordic
  • Alnylam Pharmaceuticals, Inc.
  • SIGA Technologies
  • Emergent BioSolutions Inc.
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Soligenix
  • Altimmune
  • Pluristem Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll